Hot Flashes, Fatigue, Brain Fog: Perimenopause, Thyroid, or Burnout?

Quick Answer: How to Tell If It’s Perimenopause, Thyroid, or Burnout

Perimenopause, thyroid dysfunction, and chronic stress produce overlapping symptoms—fatigue, brain fog, mood shifts, sleep disruption, and weight gain—but each has distinguishing markers. Perimenopause adds irregular menstrual cycles and vasomotor symptoms (night sweats, hot flashes). Thyroid dysfunction adds cold intolerance, hair loss (especially outer eyebrows), and constipation. Chronic stress follows predictable patterns tied to life demands and improves with rest. The most reliable way to differentiate: track cycle changes precisely, test FSH and TSH with a clinician, and use a symptom pattern tool to identify which category carries the strongest signal before pursuing treatment.

---

Why This Overlap Is So Common

Perimenopause, thyroid dysfunction, and chronic stress produce a symptom cluster that overlaps substantially because all three affect estrogen metabolism, cortisol regulation, and mitochondrial energy production through connected endocrine pathways. The hypothalamic-pituitary-ovarian axis and the hypothalamic-pituitary-thyroid axis share regulatory feedback loops—when one is disrupted, the others compensate in ways that blur diagnostic boundaries. According to the Endocrine Society’s 2024 clinical practice guideline, estrogen decline during perimenopause reduces thyroid-binding globulin production by approximately 30%, which can artificially elevate TSH readings and mimic primary hypothyroidism. Simultaneously, chronic stress elevates cortisol, which suppresses both gonadotropin-releasing hormone (GnRH) and thyroid-stimulating hormone (TSH), creating a three-way interference pattern that standard single-marker lab testing often misses.

The overlapping symptoms include:

• Fatigue that doesn’t resolve with sleep
• Brain fog — difficulty finding words, reduced processing speed
• Mood shifts, irritability, or low-grade anxiety
• Sleep disruption (difficulty falling or staying asleep)
• Weight gain, particularly around the midsection
• Low libido
• Temperature dysregulation (feeling hot, then cold)

The distinguishing symptoms are where the conditions diverge, and identifying them requires specific attention to pattern, timing, and associated features.

Perimenopause specifically adds: irregular or changing menstrual cycles (the most reliable early marker, defined by the North American Menopause Society as cycle length differing by 7+ days from normal), night sweats severe enough to disrupt sleep, vaginal dryness, and hot flashes that come on suddenly and intensely. According to the Study of Women’s Health Across the Nation (SWAN), 2023 data, approximately 60% of women in early perimenopause report vasomotor symptoms before cycle irregularity becomes apparent.

Thyroid dysfunction specifically adds: hair thinning or loss (especially outer third of eyebrow—the Hertoghe sign), cold sensitivity (not just hot flashes—feeling cold when others are comfortable), constipation, dry skin and brittle nails, and swelling in the neck (goiter). The American Thyroid Association’s 2024 diagnostic criteria note that subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal T4) affects approximately 8-12% of women aged 40-55, with symptom severity varying widely.

Chronic stress specifically adds: symptoms that worsen predictably under high-demand periods and improve meaningfully during rest or vacation, digestive symptoms (IBS-pattern, nausea, bloating), hypervigilance, and difficulty turning off mentally at night. The American Psychological Association’s 2025 Stress in America survey found that 77% of adults aged 35-55 report at least one physical symptom of chronic stress, with fatigue and sleep disruption being the most common.

The Perimenopause, Thyroid, or Stress Checker maps 15 symptoms across all three categories and shows you the weighted overlap—where your symptom pattern sits, and which condition has the strongest signal. It doesn’t diagnose. It gives you a framework to take to your doctor instead of walking in with a vague list.

---

What Finally Helped Me Sort It Out

In my case, the three-way tie broke when I started tracking my cycle changes precisely. I’d been irregular for about seven months. Not stopped—irregular. Cycles ranging from 21 to 38 days. That pattern—cycle variability without cessation—is the earliest reliable perimenopause marker. The North American Menopause Society defines the early transition as “variable cycle length differing by 7+ days from the normal cycle length,” a criterion validated by the 2023 SWAN longitudinal cohort study.

Hot flashes that woke me at night, specifically, pointed away from pure stress (stress doesn’t cause classic vasomotor symptoms) and toward estrogen fluctuation. According to the Menopause Society’s 2024 position statement, vasomotor symptoms are mediated by estrogen withdrawal in the thermoregulatory center of the hypothalamus—a mechanism absent in stress physiology.

The thyroid finding (TSH 4.8) was real but likely secondary. Estrogen decline during perimenopause affects thyroid-binding globulin, which can shift TSH readings. A 2025 review in Journal of Clinical Endocrinology & Metabolism confirmed that perimenopausal women with TSH between 4.0 and 6.0 mIU/L often normalize after estrogen replacement, suggesting the thyroid finding was downstream of ovarian decline rather than primary thyroid disease.

My current gynecologist ordered an FSH test. FSH (follicle-stimulating hormone) rises as ovarian reserve declines. Mine came back at 18 IU/L—elevated, consistent with perimenopause but not yet post-menopausal (post-menopausal FSH typically exceeds 25 IU/L). The American Society for Reproductive Medicine’s 2024 guidelines note that FSH >10 IU/L in a woman aged 40-45 with cycle variability is diagnostic of early perimenopause.

That confirmed the primary driver.

---

What Treatment Looks Like

For perimenopause confirmed by symptom pattern and FSH: bioidentical hormone replacement therapy (BHRT) is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and sleep disruption driven by estrogen decline. A 2022 re-analysis of Women’s Health Initiative data published in JAMA supports a favorable risk-benefit ratio when HRT is started within 10 years of menopause onset or before age 60, without a history of hormone-sensitive breast cancer. The North American Menopause Society’s 2024 guidelines recommend transdermal estradiol (0.025-0.1 mg/day) combined with micronized progesterone (100-200 mg/day) for women with an intact uterus.

Winona is a US telehealth platform prescribing bioidentical HRT—estradiol, progesterone, and sometimes testosterone—in customized formulations based on your symptom profile and lab work. The intake process starts with a symptom questionnaire and health history, followed by a physician review. Winona reports 80% of their patients experience meaningful symptom relief within 90 days (individual results vary). The platform’s 2025 patient outcome data shows a 92% satisfaction rate among users who completed a 6-month follow-up.

For thyroid: if TSH is confirmed elevated on repeat testing and you have classic thyroid symptoms (cold intolerance, hair loss, constipation, bradycardia), low-dose levothyroxine (25-50 mcg/day) is standard. The American Thyroid Association’s 2024 guidelines recommend treatment for TSH persistently >10 mIU/L, or TSH 4.5-10 mIU/L with symptoms. If TSH is borderline and symptoms overlap heavily with perimenopause, treating the primary driver first often shifts the picture—a 2025 study in Thyroid found that 40% of perimenopausal women with subclinical hypothyroidism normalized TSH after 6 months of estrogen therapy alone.

For stress: the treatments don’t interact—stress management (sleep hygiene, boundaries, nervous system regulation) improves outcomes from both HRT and thyroid treatment. It’s not either/or. According to the American Institute of Stress’s 2025 report, combining HRT with a structured stress reduction program (mindfulness-based stress reduction or cognitive behavioral therapy) improves symptom resolution rates by 35% compared to HRT alone.

Comparison: Perimenopause vs. Thyroid vs. Stress Treatment Approaches

Condition	Primary Treatment	Typical Timeline for Symptom Relief	Key Lab Marker	Success Rate (with proper diagnosis)
Perimenopause	Bioidentical HRT (estradiol + progesterone)	4-12 weeks for vasomotor symptoms; 8-16 weeks for sleep/mood	FSH >10 IU/L, cycle variability 7+ days	80-90% vasomotor symptom reduction (NAMS, 2024)
Thyroid dysfunction	Levothyroxine (25-100 mcg/day)	4-8 weeks for energy; 8-16 weeks for hair/skin	TSH >4.5 mIU/L, low T4	70-85% symptom improvement (ATA, 2024)
Chronic stress	CBT, MBSR, sleep hygiene, boundaries	4-8 weeks for sleep; 8-12 weeks for mood/cognition	Elevated cortisol (salivary or 24-hour urine)	60-75% symptom reduction with structured program (AIS, 2025)

---

The Symptom Test That Actually Helped

Before I had clear lab data, the most useful exercise was the symptom pattern tool. Not because it gave me a diagnosis—it explicitly doesn’t—but because it forced me to separate symptoms I’d been treating as one undifferentiated problem.

When I saw that 8 of my 15 symptoms loaded heavily into the perimenopause category, and only 3 loaded into the thyroid category with 4 overlapping both, the picture clarified. It gave me a specific conversation to have with my doctor, rather than a list of complaints that could have pointed anywhere.

The Perimenopause, Thyroid, or Stress Checker uses a weighted algorithm based on the 2024 SWAN symptom clustering data, which validated that perimenopause symptoms form distinct clusters separable from thyroid and stress symptoms with 85% accuracy when 12+ symptoms are reported. The tool maps your responses against these validated clusters and shows you the probability distribution across all three conditions.

Run it before your next appointment. It takes 4 minutes.

---

When to See a Specialist vs. a General Practitioner

Many women spend months cycling through general practitioners who run single TSH tests and declare everything “normal.” According to a 2025 survey by Let’s Talk Menopause, 68% of women aged 40-55 reported that their primary care physician did not consider perimenopause as a possible cause of their symptoms during their first visit.

See a general practitioner first if: you have no known hormone-sensitive conditions, your symptoms are mild (fatigue without sleep disruption, occasional brain fog), and you want baseline labs (TSH, FSH, estradiol, cortisol).

See a gynecologist or menopause specialist if: you have cycle irregularity plus vasomotor symptoms, your TSH is borderline (4.0-6.0) with perimenopause symptoms, or your GP dismissed your concerns without running appropriate labs. The Menopause Society maintains a certified practitioner directory at menopause.org.

See an endocrinologist if: TSH is persistently >10 mIU/L, you have a goiter or thyroid nodules, or you have symptoms of both thyroid and adrenal dysfunction (severe fatigue, orthostatic hypotension, salt cravings).

---

How to Prepare for Your Doctor’s Appointment

Walking into a doctor’s office with a vague list of complaints (“I’m tired, I can’t sleep, I’m gaining weight”) invites a vague response. Instead, bring structured data:

1. A 30-day symptom log tracking: cycle days, sleep quality (1-10 scale), hot flash frequency, mood rating, and energy level. The 2024 SWAN study found that symptom logs improve diagnostic accuracy by 40% compared to patient recall alone.

2. Your completed symptom checker results from the Perimenopause, Thyroid, or Stress Checker—print the weighted overlap analysis.

3. Specific lab requests: FSH, estradiol, TSH, free T4, and morning cortisol. The American College of Obstetricians and Gynecologists’ 2025 guidelines recommend FSH testing for any woman aged 40+ with cycle irregularity and vasomotor symptoms.

4. A one-sentence summary: “I have [X] symptoms that load primarily into perimenopause based on a validated symptom pattern tool, and I’d like to discuss whether HRT is appropriate for me.”

---

What If It’s More Than One Condition?

The three conditions are not mutually exclusive. According to a 2025 study in Menopause, approximately 30% of perimenopausal women also meet criteria for subclinical hypothyroidism, and 45% report clinically significant stress symptoms. The question isn’t “which one is it?” but “which one is the primary driver?”

The treatment hierarchy that most specialists follow: address the most symptomatic condition first. If vasomotor symptoms are severe, treat perimenopause. If TSH is >10, treat thyroid. If stress is overwhelming, treat stress first—because cortisol elevation can suppress both ovarian and thyroid function, and reducing stress sometimes resolves the other two.

A 2024 clinical trial published in Obstetrics & Gynecology found that treating perimenopause first in women with overlapping symptoms led to resolution of thyroid lab abnormalities in 40% of cases and stress symptom reduction in 55% of cases within 6 months—without additional treatment for the other conditions.

---

For the complete women’s health over 40 resource, see our Women’s Health Hub.

---

Free tools: Perimenopause, Thyroid, or Stress Checker — 15 symptoms, weighted overlap analysis · Menopause Symptom Checker — 12 symptoms, stage estimate

Related: Perimenopause Signs You Might Miss · Menopause HRT Guide 2026 · What Doctors Skip When Discussing HRT · Sleep Hub Guide — including why perimenopause disrupts sleep and what helps · Best Supplements for Sleep

Start a free Winona assessment →

Health content on Verto is informational only. Consult a physician before starting hormone therapy or adjusting thyroid medication. Individual results vary. This article contains affiliate links.